LEISHMANIASIS: NUEVOS TRATAMIENTOS, MECANISMOS DE ACCIÓN Y SUS IMPLICACIONES

Omar Geovanny Perez Ortiz, Adriana Maldonado Rozo

Resumen


Resumen


Los tratamientos para el control de la Leishmaniasis se fundamentan casi exclusivamente en antimoniales pentavalentes, compuestos de alta toxicidad para el organismo. Este tipo de medicación tiene una buena efectividad en pacientes inmunocompetentes, pero en personas inmunosuprimidas de zonas endémicas la eficacia se ha visto disminuida y se han presentado cada vez más casos de resistencia al tratamiento, razón que ha obligado a la industria farmacéutica a desarrollar nuevos medicamentos que conserven la efectividad, disminuyan la toxicidad y en lo posible ejerzan un papel estimulante en el desarrollo de la respuesta inmune del individuo hacia el parásito para que puedan ser utilizados con éxito en pacientes con alteraciones del sistema inmune. La presente revisión tiene como objeto desarrollar una breve descripción de estos nuevos tratamientos, sus mecanismos de acción y las implicaciones que tienen en las personas que son tratados con ellos.


Texto completo:

PDF

Referencias


BIBLIOGRAFÍA

Adler, S., and M. Ber. (1941). The transmission of

Leishmania tropica by the bite of Phlebotomus papatasii.

Indian J. Med. Res. Vol 29:803–809.

Ambroise-Thomas, P. (2001). Parasitic diseases

a n d i m m u n o d e fi c i e n c i e s . P a r a s i t o l o g y . Vo l

(Suppl.):s65–s71.

Ahuja, S. S., R. L. Reddick, N. Sato, E. Montalbo,

V. Kostecki, W. Zhao, M. J. Dolan, P. C. Melby, and S. K.

Ahuja., (1999). Dendritic cell (DC)-based anti-infective

strategies: DCs engineered to secrete IL-12 are a potent

vaccine in a murine model of an intracellular infection. J.

Immunol. 163: 3890–3897.

Berman, J. (2001). Leishmaniasis. Current

Treatment Options in Infectious Diseases. Vol 3: 333-336.

Berman, J. D. 1997. Human leishmaniasis: clinical,

diagnostic, and chemotherapeutic developments in the last

years. Clin. Infect. Dis. Vol 24:684–703.

Beckers T., Voegeli R., Hilgard P., (1994).

M o l e c u l a r a n d c e l l u l a r e f f e c t s o f

hexadecylphosphocholine (Miltefosine) in human myeloid

leukaemic cell lines. Eur. J. Cancer. 30A:2143-50.

Blitterswijk V.W.J, Hilkmann H, Storme GA.,

(1987). Accumulation of an alkyl lysophospholipid in

tumor cell membranes affects membrane fluidity and tumor

cell invasion. Lipids;22:820–3.

Bibby D. C., Davies N. M., Tucker I. G. (2000).

Mechanisms by which cyclodextrins modify drug release

from polymeric drug delivery systems. International

Journal of Pharmaceutics. Vol 197: 1–11

Bryceson, A. 2001. A policy for leishmaniasis with

respect to the prevention and control of drug resistance.

Trop Med Int Health. Vol 6: 928-934.

Croft S.L. (2001). Monitoring drug resistance in

leishmaniasis. Tropical Medicine and International Health.

Vol 6 (11): 899-905.

Davidson, R. N., Martino L., Gradoni L., Giacchino

R., Gaeta G.B., Pempinello R., Scotti S., Cascio A.,

Castagnola E., Maisto A., Gramiccia M., Caprio D.,

Wilkinson R.J. and Bryceson A.D. (1996). Short-course

treatment of visceral leishmaniasis with liposomal

amphotericin B (AmBisome). Clin. Infect. Dis. Vol 22:

–943.

Demicheli C., Ochoa R., Da Silva J.B.B., Falcäo C.,

Rossi B., De Melo A.L., Sinisterra R.D., and Frézard F.

(2004). Oral delivery of Meglumine Antimoniate-β-

Cyclodextrin complex for treatment of Leishmanisis.

Antimicrobial agents and Chemotheraphy. J. Vol 48 (1):

-103.

Dzamitika S.A., Falcao C.A.B., Oliveira F.B.,

Marbeuf C., Garnier-Suillerot A., Demicheli C., Rossi-

Bergmannb B., Frezard F. (2006). Role of residual Sb(III)

in meglumine antimoniate cytotoxicity and MRP1-

mediated resistance. Chemico-Biological Interactions Vol.

: 217–224

E i b l , H . , U n g e r , C . ( 1 9 9 0 ) .

Hexadecylphosphocholine: a new and selective antitumor

drug. Cancer Treat. Rev. Vol 17: 233-242.

Escobar, P., Matu, S., Marques, C., Croft, S.L.,

0 0 2 . S e n s i t i v i t i e s o f L e i s h m a n i a s p e c i e s t o

hexadecylphosphocholine (miltefosine), ET-18- OCH(3)

(edelfosine) and amphotericin B. Acta Trop. Vol 81: 151-

Guerin, P. J., Olliaro P., Sundar S., Boelaert M.,

Croft S. L., Desjeux P., Wasunna M. K. and Bryceson A.

(2002). Visceral Leishmanisis: Current Status of Control,

Diagnosis, and Treatment, and a proposed research and

development agenda. The Lancet Infectious Diseases. Vol

: 494-500.

Hedges, A. R. (1998). Industrial applications of

cyclodextrins. Chemistry Review. Vol 98: 2035-2042.

Hilgard, P., Klener T., Stekar J., and Unger C.

(1993). Alkylphosphocholines: a new class of membrane

active anticancer agents. Cancer Chemoter. Pahrmacol.

:90-95.

Hochhuth C. H., Vehmeyer K., Eibl H., Unger C.

(1992). Hexadecyolphosphocholine induces interferongamma

secretion and expresión of GM-CSF mRNA in

human mononuclear cells. Cell Immunol. 141:161-8.

Hockhertz, S., G. Franke, I. Paulini, and M.-L.

Lohmann-Matthes. (1991). Immunotherapy of murine

visceral leishmaniasis with murine recombinant interferong

and MTP-PE encapsulated in liposomes. J. Interferon

Res. Vol 11(3):177-185.

Irie T., Uekama K. (1997). Pharmaceutical

Applications of Cyclodextrins. III. Toxicological Issues and Safety Evaluation. Journal of Farmaceutical Sciences.

Vol 86: 147-162.

Kapoor, P., Sachdev M. and Madhibala R. (2000).

Inhibition of glutathione synthesis as a hemotherapeutic

strategy for leishmaniasis. Trop. Med. Int. Health. Vol 6:

–442.

Langer R. (1990). New Methods of drug delivery.

Science, Vol 249: Pág. 1527-1532.

Lasic, D. D. (1998). Novel application of

liposomes. Trends in Biotechnology. Vol 16: 307-312.

Li J., Xiao H., Li J., Zhong Y. (2004). Drug carrier

systems based on water-soluble cationic B-ciclodextrine

polymers. International Journal of Pharmaceutics. Vol 278:

–342

Loftsson T. And Masson M. (2001). Cyclodextrins

in topical drug formulations: theory and practice.

International Journal of Pharmaceutics. Vol 225: 15-30.

L o f t s s o n T. a n d B r e w s t e r M . E . ( 1 9 9 6 ) .

Pharmaceutical applications of cyclodextrins. Drug

solubilization and stabilization. Pharmaceutical Sciences,

Vol 85 (10): 1017-1025.

Lucumi, A., Robledo, S., Gama V., Saravia N.

(1998). Sensitivy of Leishmania viannia panamensis Is

Correlated with the Formation of Cleaveble DNA-Protein

Complexes. Antimicrobial Agents and Chemotherapy. Vol

(8): 1990-1995.

Maldonado R. A, Pérez O.O.G, Ochoa B.R. (2007).

Formulación y evaluación in vivo de un compuesto

leishmanicida (Hexadecilfosfocolina), en sistemas de

l i b e r a c i ó n c o n t r o l a d a t i p o c i c l o d e x t r i n a . R e v i s t a

Biomédica, Vol 27 (s2): 164.

Manunza, B., Deiana S., Pintore M., Gessa C.

(1997). Structure and internal motion of solvated betacyclodextrine:

a molecular dynamics study. Journal of

Molecular Structure (Theochem). Vol 419: 133-137.

Martins P. S., Ochoa R., Pimenta A. M. C., Ferreira

L. A. M., Meloe A. L., da Silva J. B. B., Sinisterra R. D.,

Demicheli C., Frezard F. (2006). Mode of action of Bcyclodextrin

as an absorption enhancer of the water-soluble

drug meglumine antimoniate. International Journal of

Pharmaceutics. Vol 325: 39–47.

Menez C., Buyse M., Chacun H., Farinotti R.,

Barratt. G. (2006). Modulation of intestinal barrier

properties by miltefosine. Biochemical pharmacology Vol

: 486–496.

Mittal, N., Gupta N., Saksena S., Goyal N., Roy U.

and Rastogi A. K. (1998). Protective effect of Picroliv from

Picorhiza kurroa against Leishmania donovani infections

in Mesocricetus auratus. Life Sci. Vol 63: 1823–1834.

Murphy, M. L., S. Cotterell, M. Gorak, C. R.

Engwerda, and P. M. Kaye., (1998). lockade of CTLA-4

enhances host resistance to the intracellular pathogen,

Leishmania donovani. J. Immunol. Vol 161:4153–4160.

Murray, H. W., Oca, M.J., Granger, A. M. and

S c h r e i b e r R . D . ( 1 9 8 9 ) . S u c c e s s f u l r e s p o n s e t o

chemotherapy in experimental visceral leishmaniasis:

requirement for T cells and effect of lymphokines. J. Clin.

Investig. Vol 83: 1254–1259.

Murray, H. W. (1990). Effect of continuous

administration of interferongamma in experimental

visceral leishmaniasis. J. Infect. Dis. Vol 161:992–994.

Murray, H. W., J. Hariprashad, and R. Fichtl. (1993

a.). Treatment of experimental visceral leishmaniasis in a Tcell-

deficient host: response to amphotericin B and

pentamidine. Antimicrob. Agents Chemother. Vol

:1504–1505

Murray, H. W., Miralles G. D., Stoeckle M. Y. and

McDermott D. F. (1993 b.). Role and effect of Interleukin-2

in experimental visceral leishmaniasis. J. Immunol. Vol

: 929–934.

Murray, H. W., and J. Hariprashad. (1995).

Interleukin 12 is effective treatment for an established

systemic intracellular infection: experimental visceral

leishmaniasis. J. Exp. Med. Vol 181:387–391.

M u r r a y, H . W. , J u n g b l u t h A . , R i t t e r E . ,

Montelibano C. and Marino M.W. (2000). Visceral

leishmaniasis in mice devoid of tumor necrosis factor and

response to treatment. Infect. Immun. Vol 68: 6289–6293.

Murray H.W. (2001). Minireview, Clinical and

E x p e r i m e n t a l A d v a n c e r i n Tr e a t m e n t o f Vi s c e r a l Leishmaniasis. Antimicrobial Agents and Chemotherapy.

Vol 45 (8): 2185-2197.

Ochoa, R. (2003). Síntese e formulacao de

compostos de antimonio ativos contra a Leishmanioses em

sistemas de liberacao do tipo: ciclodextrinas, polímeros

biodegradáveis e lipossomas. Universidade Federal de

Minas Gerais, Belo Horizonte.

Ohkusu, K., Yoshimoto T., Takeda K., Ogura T.,

Kashiwamura S.-I., Iwakura Y., Akira S., Okamura H. and

Nakanishi K. (2000). Potentiality of interleukin 18 as a

useful reagent for treatment and prevention of Leishmania

major infection. Infect. Immun. Vol:68, Pág. 2449–2456.

Papagiannaros A., Bories C., Demetzos C., Loiseau

P.M. (2005). Antileishmanial and trypanocidal activities of

new miltefosine liposomal formulations. Biomedicine &

Pharmacotherapy Vol 59: 545–550

Pérez-Victoria J.M., Pérez-Victoria F.J., Castanys S. y

Gamarro F. (2006). Estrategias terapéuticas y bases

moleculares de la resistencia a fármacos frente a la

leishmaniasis. Instituto de Parasitología y Biomedicina

"López-Neyra" (CSIC) Parque Tecnológico de Ciencias de

la Salud Avda. del Conocimiento, s/n. 18100 Armilla,

GRANADA (SPAIN). josepv@ipb.csic.es

Perez-Victoria J.M., Perez-Victoria F.J., Parodi-

Talice I.A, Jimenez A.G., Ravelo S.C. and Gamarro F.

(2001). Alkyl-lysophospholipid resistance in multidrugresistant

Leishmania tropica and chemosensitization by a

n o v e l P g l y c o p r o t e i n - l i k e t r a n s p o r t e r m o d u l a t o r.

Antimicrob Agents Chemother Vol 45: 2468-2474.

Pintado V., Lopez-Velez R. (2001). HIV –

associated visceral leishmaniasis. Clinical Microbiology

Infection. Vol 7: 291-300.

R a j e w s k i R . A . a n d S t e l l a V. J . ( 1 9 9 6 ) .

Pharmaceutical Applications of Cyclodextrins. 2. In vivo

Delivery. Journal of Pharmaceutical Sciences, Vol 85 (11):

-1169.

Singh M., Sharma R. y Banerjee U. C. (2002).

B i o t e c h n o l o g i c a l a p p l i c a t i o n s o f c y c l o d e x t r i n s .

Biotechnology Advances. Vol 20: 341-359.

Singh S. (2006). New developments in diagnosis

of leishmaniasis. Indian J. Med. Res. Vol 123: 311-330.

Soto J., Berman J. (2006). Treatment of New

Wo r l d c u t a n e o u s l e i s h m a n i a s i s w i t h m i l t e f o s i n e , Transactions of the Royal Society of Tropical Medicine and

Hygiene. Vol 100S: S34—S40

Soto J., Toledo J.T. (2007). Oral miltefosine to treat

new world cutaneous leishmaniasis. The Lancet Infectious

Diseases, Vol 7: 7.

Sundar S., Sinha P.R., Agrawal N. K. (1998). A

cluster of cases of severe cardiotoxicity among kala-azar

patients treated with a high-osmolarity lot of sodium

antimony gluconate. American Tropical Medicine and

Hygiene. Vol 59: 193-203.

Sundar S. (2001). Drug resistance in Indian

visceral leishmaniasis. Trop. Med. Int. Health. Vol 6: 849-

Sypek, J. P., C. L. Chung, S. E. H. Mayor, J. M.

Subramanyam, S. J. Goldman, D. D. Sieburth, S. F. Wolf, &

S c h a u b R . G . . ( 1 9 9 3 ) . R e s o l u t i o n o f c u t a n e o u s

leishmaniasis: interleukin 12 initiates a protective T helper

type 1 immune respoonse. J. Exp. Med. Vol 177: 1797–1802.

Thakur, C. P., Kanyok T. P., Pandey A. K., Sinha G.

P., Messick C. and Olliaro P. (2000). Treatment of visceral

l e i s h m a n i a s i s w i t h i n j e c t a b l e p a r a m y o m y c i n (aminosidine). An open-label randomized phase-II clinical

study. Trans. R. Soc. Trop. Med. Hyg. Vol 94: 432–433.

Thakur, C. P., R. K. Singh, S. M. Hassan, R. Kumar,

S. Narain, and Kumar, A. (1999). Amphotericin B

deoxycholate treatment of visceral leishmaniasis with

newer modes of administration and precautions: a study of

cases. Trans. R. Soc. Trop. Med. Hyg. Vol 93: 319–323.

Vázquez T.J. (2000). Ciclodextrinas. Universidad

de Santiago. Departamento de Química Física, Facultad de

Ciencias, Lugo, España. 1-19.

Vásquez L., Scorza J., Dagert V., Scorza J.V.,

Vicuna-Fernandez N., Petit de Peña Y., López S., Bendeza

H-, Rojas E., Vásquez L., and Pérez B. (2006).

Pharmacokinetics of Experimental Pentavalent Antimony

After Intramuscular Administration in Adult Volunteers.

Current Therapeutic Research. Vol. 67 (3): 193-203.

Villiers, A. (1981). Chimie Organic – sur la

transformation de la fécule en dextrine per le ferment

butyrique. Compt. Render. Vol 112: 536-540

Wieder T, Orfanos CE, Geilen CC., (1998).

Induction of ceramide-mediated apoptosis by the

anticancer phospholipid analog hexadecylphosphocholine.

J Biol Chem;273:11025–31.

Zeisig R., Rudolf M., Eue I., Arndt D. (1995).

Influence of hexadecylphosphocholine on the release of

tumor necrosis factor and nitroxide from peritoneal

macrophages in vitro. J. Cancer Res. Clin. Oncol. 121: 69-


Enlaces refback

  • No hay ningún enlace refback.